Amicus Therapeutics (LTS:0HF9) 3-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amicus Therapeutics 3-Year EBITDA Growth Rate?

Amicus Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $0.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amicus Therapeutics was 85.70% per year. The lowest was -81.70% per year. And the median was 14.80% per year.

Competitive Comparison of Amicus Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Amicus Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's 3-Year EBITDA Growth Rate falls into.

Amicus Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Amicus Therapeutics (LTS:0HF9) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Amicus Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (LTS:0HF9) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics Headlines

No Headlines